NCT05221372 ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
| NCT ID | NCT05221372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2017-02-02 |
| Primary Completion | 2031-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,300 participants in total. It began in 2017-02-02 with a primary completion date of 2031-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Able to understand the written informed and able to give informed consent * Locally advanced or metastatic NSCLC with oncogenic driver mutation * Treatment with TKI according to standard of care Exclusion Criteria: * Unable to draw blood for study purposes
Contact & Investigator
Anne-Marie Dingemans, MD, PhD
PRINCIPAL INVESTIGATOR
Erasmus Medical Center
Frequently Asked Questions
Who can join the NCT05221372 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05221372 currently recruiting?
Yes, NCT05221372 is actively recruiting participants. Contact the research team at a.dingemans@erasmusmc.nl for enrollment information.
Where is the NCT05221372 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT05221372 clinical trial?
NCT05221372 is sponsored by Erasmus Medical Center. The principal investigator is Anne-Marie Dingemans, MD, PhD at Erasmus Medical Center. The trial plans to enroll 1,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.